{
  "docId": "019de073-42e0-708e-bbdb-4616fa343de3",
  "docSlug": "252a92bcbab8bda657ee7494bf765251",
  "documentTitle": "BioAtla | Investor Presentation Deck | 37 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 24,
  "pageCount": 37,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "The slide uses a 2x2 grid of metrics to frame the market problem, followed by specific target population and success threshold data.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-42e0-708e-bbdb-4616fa343de3/24",
  "deckHref": "/decks/019de073-42e0-708e-bbdb-4616fa343de3",
  "deckJsonHref": "/decks/019de073-42e0-708e-bbdb-4616fa343de3.json",
  "deckAnchorHref": "/decks/019de073-42e0-708e-bbdb-4616fa343de3#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.03,
        "y": 0.75
      },
      "kind": "list",
      "text": "Target population: ~5K ROR2+ addressable 2L+ patients/year in the U.S., based on a ROR2 positivity rate of ~10%. Internal success threshold: 2L+ ORR of ~20% (approvability bar); 25%+ (commercially relevant) following BA3011 monotherapy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "caa579c4-6978-43d4-b72d-9910d7db769b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.03,
        "y": 0.195
      },
      "kind": "metric",
      "text": "~1.3MM people in the U.S. living with melanoma",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0bd40d7e-0d84-440e-9440-88285e927665",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.35,
        "y": 0.195
      },
      "kind": "metric",
      "text": "~100K newly diagnosed invasive cases / year (U.S.)",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2be1cce0-58be-4164-bb2a-1c0b92861c24",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.35,
        "y": 0.45
      },
      "kind": "metric",
      "text": "30-40% initial responders progress",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9299692a-401a-4aea-9103-60ab6620a288",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.03,
        "y": 0.45
      },
      "kind": "metric",
      "text": "~50% do not respond to PD-1 therapy in 1L setting",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab72ff9d-e596-4e08-bf81-368f96e702d7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.7,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "Available Treatment: 1L: ICIs 33% - 50% ORR; (BRAF / Mek inhibitors for BRAF+). 2L+: ICIs 9% - 28% ORR (mono – combo, respectively)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "432339b7-568e-44d0-ad81-3054c3c3ad85",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.03,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Clarivate, Disease Landscape and Forecast: Malignant Melanoma (2022)... 1L, first line; 2L+, second line or greater; ICIs – Immune checkpoint inhibitors.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31a44ede-ca4c-4f7a-9daa-de94d5419442",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "Potential market opportunity in metastatic melanoma",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fbaa5827-5bbf-4ec9-9830-f5ad088ae148",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Market Segmentation Pyramid",
      "slug": "market-segmentation-pyramid",
      "agent": null,
      "layer": "slide",
      "matchId": "f4fc1a4e-6da9-4438-98b0-e94305a49fd1",
      "evidence": "list/bullet: Target population: ~5K ROR2+ addressable 2L+ patients/year in the U.S., based on a ROR2 positivity rate of ~10%",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 27,
      "from": 10,
      "beatId": "c5004055-d5ec-4e67-8d3c-a6006b26dc07",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The deck presents encouraging Phase 1 and 2 results for various indications, demonstrating traction.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 27,
      "from": 10,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "70b35119-d82b-4aab-a655-ee1318f5401a",
      "evidence": "The deck presents encouraging Phase 1 and 2 results for various indications, demonstrating potential for quick wins and big bets.",
      "position": 2,
      "objective": "What are the potential quick wins and big bets for BioAtla's CAB technology?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}